

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection
Flow cytometry: BD FACSuite (1.0.5.3841) or BD FACSDiva (8.0.2) software
RNA-seq: Illumina HiSeq2500 System

Data analysis
Flow cytometry: FlowJo (10.4.2)
Immunofluorescence: NIS-Elements (4.11.0), ImageJ (1.53a)
RNA-seq: cutadapt (1.8.1), fastx-toolkit (0.0.13), TopHat (2.1.1), Cufflinks (2.1.1), GSEA software (4.0.2), gplots (3.0.4)
Statistics: GraphPad Prism (9.0.0)

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Source data are provided with this paper. RNA-seq data are available in sequence read archive (SRA) database (accession ID: PRJNA673672). Metabolome analysis data are available in MassIVE (accession ID: MSV000086816). The datasets generated or analyzed during the current study are available from the corresponding author (kitamura@ims.u-tokyo.ac.jp) on reasonable request.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Sample sizes were indicated in the legend of each Figure and Supplementary Figure. No statistical methods were used to predetermine sample sizes. We determined sample sizes by referring to previously published paper in the field. Basically, at least triplicate experiments were performed to meet the minimal requirements for statistical analysis.
Data exclusions	No data were excluded from the analyses.
Replication	All experiments were replicated at least twice. All attempts to replication were successful.
Randomization	For experiments using cultured cells, all cells in each experiments were derived from the same pools of parent cells. All animals were maintained in the same environment and were randomly assigned to the experimental groups.
Blinding	For data automatically collected by instruments, such as flow cytometry, complete blood count, immunoblotting, and RNA-seq analysis, researchers were not blinded as observer bias is expected not to affect the results. For data manually collected by researchers, such as counting γ -h2ax foci and measuring comet tail moment, researchers were blinded during data analyses.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Antibodies

Antibodies used

(For flow cytometry analysis)

CD5 (BioLegend, 100604)
 B220 (BioLegend, 103204)
 CD11b (BioLegend, 101204)
 Gr-1 (BioLegend, 108404)
 Ter119 (BioLegend, 116204)
 CD150-PE (BioLegend, 115904)
 c-kit-PE-Cy7 (BioLegend, 105814)
 Sca1-APC (BioLegend, 108112)
 CD48-Brilliant Violet 421 (BioLegend, 103427)
 Streptavidin-Brilliant Violet 605 (BioLegend, 405229)
 CD41-APC (BioLegend, 133914)
 CD11b-PE (eBioscience, 12-0112-85)
 CD45R/B220-PE/Cy7 (BioLegend, 103224)
 CD3-APC (100236)
 CD45.2-APC/Cy7 (BioLegend, 109824)
 Sca1-Brilliant Violet 785 (BioLegend, 108139)

CD48-APC-Cy7 (BioLegend, 103431)
 p-H2A.X (Cell Signaling Technology, #9718)
 Akt (Pan) (Cell Signaling Technology, #4691)
 Phospho-Akt (Ser473) (Cell signaling Technology, #4060)
 Ki-67-eFluor660 (eBioscience, 50-5698-82)
 Annexin V-APC (BioLegend, 640920)
 Alexa Fluor 647 secondary antibody (Invitrogen)
 Phospho-S6 (Ser235/236) (Cell Signaling Technology, #4858)
 isotype control (abcam, ab172730) antibody

(For IP-WB experiment)

AKT1/2/3 (Santa Cruz Biotechnology, sc-81434)
 Akt (Pan) (Cell Signaling Technology, #4691)
 Phospho-Akt (Ser473) (Cell signaling Technology, #4060)
 BAP1 (Santa Cruz Biotechnology, sc-28383)
 FLAG (Sigma, F1804)
 GAPDH (Cell signaling Technology, #5174)
 Myc (Roche, #11814150001)
 HA (Roche, #11867423001)
 α -Tubulin (SIGMA)
 Lamin B1 (Santa Cruz Biotechnology, sc-374015)

(For Immunofluorescence experiment)

Tom20 ((Santa Cruz Biotechnology, sc-11415)
 p-H2A.X (Cell Signaling Technology, #9718)
 Alexa Fluor 568 goat anti-rabbit IgG (Invitrogen, A11011)

Validation

All antibodies are commercially available and those specificities were tested by manufactures. All vendors and catalog numbers of antibodies are listed above and detailed information is available on the websites. For flow cytometry analyses, specificity was evaluated using the proper control including isotype control antibody. For IP-WB experiments, specificity was validated using vector control or IgG control antibody. The validation of each primary antibodies for the reactive species and applications are described below.

CD5 (BioLegend, 100604) - Reactive species: Mouse, Application: Flow cytometry
 B220 (BioLegend, 103204) - Reactive species: Mouse, Human (Cross-Reactivity: Cat (Feline)), Application: Flow cytometry
 CD11b (BioLegend, 101204) - Reactive species: Mouse, Human (Cross-Reactivity: Chimpanzee, Baboon, Cynomolgus, Rhesus, Rabbit (Lapine)), Application: Flow cytometry
 Gr-1 (BioLegend, 108404) - Reactive species: Mouse, Application: Flow cytometry
 Ter119 (BioLegend, 116204) - Reactive species: Mouse, Application: Flow cytometry
 CD150-PE (BioLegend, 115904) - Reactive species: Mouse, Application: Flow cytometry
 c-kit-PE-Cy7 (BioLegend, 105814) - Reactive species: Mouse, Application: Flow cytometry
 Sca1-APC (BioLegend, 108112) - Reactive species: Mouse, Application: Flow cytometry
 CD48-Brilliant Violet 421 (BioLegend, 103427) - Reactive species: Mouse, Application: Flow cytometry
 Streptavidin-Brilliant Violet 605 (BioLegend, 405229) - Human, Mouse, Rat, All Species, Application: Flow cytometry
 CD41-APC (BioLegend, 133914) - Reactive species: Mouse, Application: Flow cytometry
 CD11b-PE (eBioscience, 12-0112-85) - Reactive species: Dog, Fish, Human, Mouse, Application: Flow cytometry
 CD45R/B220-PE/Cy7 (BioLegend, 103224) - Mouse, Human (Cross-Reactivity: Cat (Feline)), Application: Flow cytometry
 CD3-APC (BioLegend, 100236) - Reactive species - Mouse, Application: Flow cytometry
 CD45.2-APC/Cy7 (BioLegend, 109824) - Reactive species: Mouse, Application: Flow cytometry
 Sca1-Brilliant Violet 785 (BioLegend, 108139) - Reactive species: Mouse, Application: Flow cytometry
 CD48-APC-Cy7 (BioLegend, 103431) - Reactive species: Mouse, Application: Flow cytometry
 p-H2A.X (Cell Signaling Technology, #9718) - Reactive species: Human, Mouse, Rat, Monkey, Application: Western Blotting, Immunohistochemistry, Immunofluorescence, Flow cytometry
 Akt (Pan) (Cell Signaling Technology, #4691) - Reactive species: Human, Mouse, Rat, Monkey, D. melanogaster, Application: Western Blotting, Immunoprecipitation, Immunohistochemistry, Immunofluorescence, Flow cytometry
 Phospho-Akt (Ser473) (Cell signaling Technology, #4060) - Reactive species: Human, Mouse, Rat, Hamster, Monkey, D. melanogaster, Zebrafish, Bovine, Application: Western Blotting, Immunoprecipitation, Immunohistochemistry, Immunofluorescence, Flow Cytometry
 Ki-67-eFluor660 (eBioscience, 50-5698-82) - Reactive species: Rat, Fish, Mouse, Human, Application: Flow cytometry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry
 Annexin V-APC (BioLegend, 640920) - Reactive species: All mammalian species, Application: Flow cytometry
 Phospho-S6 (Ser235/236) (Cell Signaling Technology, #4858) - Reactive species: Human, Mouse, Rat, Monkey, Mink, S. cerevisiae, Application: Western Blotting, Immunohistochemistry, Immunofluorescence, Flow cytometry
 isotype control (abcam, ab172730) antibody: Application: Immunocytochemistry, Immunofluorescence, Immunohistochemistry, Flow cytometry, ChIP-sequencing, Immunoprecipitation
 AKT1/2/3 (Santa Cruz Biotechnology, sc-81434) - Reactive species: Mouse, Rat, Human, Canine, Application: Western blotting, Immunoprecipitation
 BAP1 (Santa Cruz Biotechnology, sc-28383) - Reactive species: Mouse, Rat, Human, Application: Western blotting,

Immunoprecipitation, Immunofluorescence, Immunohistochemistry, ELISA
 GAPDH (Cell signaling Technology, #5174) - Reactive species: Human, Mouse, Rat, Monkey, Application: Western blotting, Immunohistochemistry, Immunofluorescence
 Lamin B1 (Santa Cruz Biotechnology, sc-374015) - Reactive species: Mouse, Rat, Human, Application: Western blotting, Immunoprecipitation, Immunofluorescence, ELISA
 Tom20 (Santa Cruz Biotechnology, sc-11415) - Reactive species: Mouse, Rat, Human, Application: Western blotting, Immunoprecipitation, Immunofluorescence, Immunohistochemistry, ELISA
 α -Tubulin (SIGMA, T9026) - Reactive species: Bovine, Rat, Yeast, Human, Mouse, Chicken, Fungi, Amphibian, Application: Western blotting, Immunofluorescence
 FLAG (Sigma, F1804) - Application: Western blotting, ELISA
 Myc (Roche, #11814150001) - Application: Western blotting
 HA (Roche, #11867423001) - Application: Western blotting, Immunocytochemistry, Immunoprecipitation, ELISA.

Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)	293T was obtained from ATCC (CRL-11268). We generated PlatE (Morita et al. Gene Therapy. 7(12), 2000) and cSAM (Inoue et al. Leukemia. 29(4), 2015) cells.
Authentication	All cell lines used in this study were authenticated by short-tandem repeat analyses.
Mycoplasma contamination	Cells were tested for mycoplasma contamination and the results were negative.
Commonly misidentified lines (See ICLAC register)	We did not use commonly misidentified lines in this study.

Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals	Wild-type C57BL/6J mice were bred in-house. Conditional ASXL1-MT KI mice have been generated in our laboratory and crossed to Vav-Cre or Mx1-Cre transgenic mice. p53 ^{-/-} mice were provided by K. Matsuda (Tokyo University). All mice have the genetic background of C57BL/6J. Male and female mice were equally used for all experiments. Experiments were performed with 6 to 12-week-old for young mice or 20 to 24-month-old for aged mice.
Wild animals	No wild animals were used in this study.
Field-collected samples	No field-collected samples were used in this study.
Ethics oversight	The experiments were approved by the Committee on the Ethics of Animal Experiments and all these mice were maintained according to the guidelines of the Institute of Laboratory Animal Science (PA13-19 and PA16-31).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation	Bone marrow cells were obtained by flushing long bones (femurs and tibias) in phosphate-buffered saline (PBS) containing 2% heat-inactivated FBS (FACS buffer). Cell suspensions were lysed with erythrocyte lysis buffer (150 mM NH ₄ Cl, 10 mM KHCO ₃ , 100 μ M EDTA-Na ₂), filtered through a 40 μ m filter. Cells were then stained with fluorochrome-conjugated antibodies. For intracellular staining, cells were fixed in 4% paraformaldehyde for 10 min at room temperature, permeabilized with 0.2% Triton X-100 for 15 min at room temperature and blocked with 5% goat serum for 15 min at room temperature. Fixed cells were subsequently stained with primary and secondary antibodies.
Instrument	Flow cytometry experiments were performed using FACSVerse or FACSAria.
Software	Data were collected with BD FACSsuite or BD FACSDiva software and were analyzed with FlowJo software.
Cell population abundance	Cell populations were sorted to >95% purity post sort in pilot experiments, as determined by flow cytometry.

Gating strategy

Gating strategies are shown in Supplementary Figure 1. In brief, cells were gated for size exclusion (FSC-A/SSC-A) followed by doublet exclusion (FSC-H/FSC-W and SSC-H/SSC-W). The following gating were performed as indicated in Supplementary Figure 1. Boundaries between negative and positive were determined by single stained control.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.